A b c d 30% AcN 30% Organic (143 Features) FT 200 500 1000 #Features25 18 43 43 CV0.2 0.3 0.3 0.5 R...

Preview:

Citation preview

0 100 200 300 400 500 600 700

2D_25

2D_50

2D_100

2D_200

DS

Cleanup

1D

2D

Total Number of Peaks

Met

hods

Opt

imiz

atio

na

b

cd

6 8 10 12 14 16 18 20

6

8

10

12

14

16

18

20

Ln

(I)

Ln(I)

FT 200 500 1000

Color: • • • •Features: 25 18 43 43% CV: 0.2 0.3 0.3 0.5R2: 0.99 0.98 0.96 1.0

Peak Reproducibility from 30% Fractions

143 Features129 < 10 kDa7 > 10 kDa < 20 kDa6 > 20 kDa

30% AcN30% Organic (143 Features)

FT 200 500 1000#Features 25 18 43 43CV 0.2 0.3 0.3 0.5R2 0.99 0.98 0.96 1.0

6 8 10 12 14 16 18 20

6

8

10

12

14

16

18

20

Ln

(I)

Ln(I)

FT 200 500 1000

Color: • • • •Features: 52 56 62 67% CV: 0.2 0.2 0.2 0.3R2: 0.98 0.99 0.98 0.99

237 Features205 < 10 kDa28 > 10 kDa < 20 kDa4 > 20 kDa

Peak Reproducibility from 45% Fractions

45% Organic (237 Features)

FT 200 500 1000#Features 52 56 62 67CV 0.2 0.2 0.2 0.3R2 0.98 0.99 0.98 0.99

6 8 10 12 14 16 18 20

6

8

10

12

14

16

18

20

Ln

(I)

Ln(I)

FT 200 500 1000

Color: • • • •Features: 49 73 68 63% CV: 0.4 0.2 0.3 0.3?R2: 0.99 0.99 0.97 0.91

253 Features199 < 10 kDa46 > 10 kDa < 20 kDa8 > 20 kDa

Peak Reproducibility from 80% Fractions80% Organic (258 Features)

FT 200 500 1000#Features 49 73 68 63CV 0.4 0.2 0.3 0.3R2 0.99 0.99 0.97 0.91

Met

ho

d

Supplemental Figure 1.

Pooled Serum

1) IgY-R7 Depletion Column

2) SPE w/Peptide Mactrotraps (C18/ SCX)

3) C4-RP HPLC (LC-MALDI-Spotter)

4) LC-MALDI-TOF-MS (isolate key fractions)

5) 1D-PAGE (In-gel tryptic digestion)

6) nLC-MS2

Validation by Western Blot

Increased in Ras

15626, m/z15605, m/z

6568, m/z

15605, m/z

6568, m/z

Serpina1a

1500

1000

500

0

Control Ras

Rela

tive

Inte

nsity

LysC

Rela

tive

Inte

nsity

Sub-pooled serum

IgY-R7 Depletion

C4-RP HPLC

Peptide Macrotrap

LC-MALDI Analysis

1D-PAGE on Fractions containing Peaks of Interest

In-gel Tryptic Digestion

LC-MS(MS)2 Analysis

Validation with Western Blot

Verif ication with EIA on Human Serum

Feature Increased in Kras vs. Control

6,560 6,620

m/z

Increased in Ras

15626, m/z15605, m/z

6568, m/z

15605, m/z

6568, m/z

Serpina1a

1500

1000

500

0

Control Ras

Re

lati

ve

Inte

nsi

ty

LysC

Re

lati

ve

Inte

nsi

ty

2,000

1,500

500

0

Inte

nsi

ty

C. Ras

6,568, m/z

100

50

0

Rel

. In

ten

sity

300 1,200

m/z

MS2 Sequence

Protein ID

a.b.

c.

Supplemental Figure 2.

Extracellular Membrane Cytoplasm Nuclear

Significant Hit

Receptor Ligand

Transcripton Factor

Generic Protein

Binding Protein

Transporter

Receptor

Generic Enzyme

Protease

Kinase

Legend

SupplementalFigure 3.

Recommended